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Objectives: In health technology assessment meta-analysis is used to combine 
evidence from a number of studies to inform the decision-making process. When 
evaluating new health technologies at early stages of their development, treat-
ment effects on short-term surrogate endpoints may be used to predict the effect 
on the final outcome that otherwise requires long follow-up time. Meta-analysis 
of multiple outcomes which takes into account the correlations between them is 
particularly suitable for modelling surrogate endpoints. The aim of this study was 
to investigate the choice of distributional assumptions when developing meta-
analytic methods for evaluation of surrogate endpoints. MethOds: Two bivariate 
meta-analytical models are applied to a case study in chronic myeloid leukaemia 
where overall survival (OS) proportion, is the final outcome and complete cytoge-
netic response (CCYR) rate at 12 months is a surrogate endpoint. A normal model on 
log relative risk scale for both outcomes is applied to evaluate CCYR as a surrogate 
endpoint for OS. This model is then extended by relaxing the assumption of nor-
mality by the use of binomial distributions for both outcomes. Results: The effect 
on CCYR was a significant predictor of the effect on OS. Both models gave similar 
results for the effect of CCYR on OS. However, the heterogeneity parameter was 
larger in the binomial model (τ 2= 0.09 with 95% CrI; 0.0 to 0.52) compared to normal 
case (τ 2= 0.07 with 95% CrI; 0.0 to 0.39). cOnclusiOns: The results of both models 
were similar for this case study. However, the choice of distributional assumption 
can lead to different estimates of the effect on the final outcome in other disease 
areas when the normality assumption is not suitable and consequently this can 
impact on HTA decisions.
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Objectives: The gene of CYP2C19 is highly polymorphic and influences the metab-
olism of clopidogrel. Using CYP2C19 genotype data, patients at risk of inadequate 
antiplatelet effect with clopidogrel could be identified and treated with a new 
antiplatelet agent (prasugrel or ticagrelor). This study aimed to evaluate the cost-
effectiveness of genotype-guided therapy versus universal clopidogrel treatment for 
patients with acute coronary syndrome (ACS) undergoing percutaneous coronary 
intervention (PCI). MethOds: A lifelong Markov model, from the perspective of 
healthcare provider, was designed to simulate two treatment strategies: universal 
generic clopidogrel and genotype-guided therapy (generic clopidogrel for patients 
without CYP2C19 loss-of-function (LOF) allele and new oral antiplatelet drug (prasu-
grel or ticagrelor) for patients with at least one LOF allele). Model inputs were derived 
from published meta-analysis and clinical trials. Direct medical costs and quality-
adjusted life-year (QALY) gained were the primary model outcomes. One-way and 
probabilistic sensitivity analyses were performed. Results: Base-case analyses 
illustrated that universal clopidogrel strategy cost $76,335 with 7.919 QALYs, while 
genotype-guided therapy cost $73,131 with 8.068 QALYs. With a threshold of willing-
ness-to-pay of $50,000 per QALY, genotype-guided therapy remained the preferred 
strategy throughout variations of all model inputs in one-way sensitivity analysis 
with no threshold value identified. The most influential factor was the probability 
of ischemic heart disease (IHD) state turned to death, followed by the possibility of 
post myocardial infarction state turned to death, cost of PCI and utility of IHD. In 
probabilistic sensitivity analysis, genotype-guided therapy was dominant with cost-
saving $3472 (95% confidence interval (CI): 3448-3496) and a gain of 0.2425 QALY (95% 
CI: 0.2421-0.2429) compared with universal generic clopidogrel. cOnclusiOns: 
Genotype-guided therapy appears to be the preferred strategy when comparing 
to universal generic clopidogrel treatment for patients with ACS undergoing PCI.
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Objectives: We presented an approach to jointly estimate Markov chain transi-
tion probabilities using survival models and constrained optimization to avoid the 
negative probabilities resulting from separate estimations via a case study on dia-
betes and mortality. MethOds: We used data from the National Health Interview 
Survey, 1997-2006, and built a three-state (well, diabetes, and death) Markov model 
with a cycle length of one year. In this model, the transition probability from the 
diabetes state to the well state was assumed to be zero. The other probabilities in 
the transition matrix were jointly estimated based on survival models and con-
strained optimization. First, the probability of developing diabetes and that of death 
were modeled using an exponential survival function, controlling for body mass 
index (BMI), age, and gender. Second, the nonlinear least squares approximation 
method was used to estimate the transition probability from well to well based on 
the data. Last, we simultaneously maximized the combined log-likelihood func-
tions derived from the survival functions under the constraints that the sum of 
the probabilities of all possibilities must add up to one. Results: Using individu-
als aged 50-59 as an example, the transition probability from well to diabetes was 
0.00087 for normal-weight women and 0.00081 for normal-weight men, 0.0015 for 
overweight women and 0.0014 for overweight men, and 0.0034 for obese women 
pleted the questionnaire online. A qualitative analysis of the data, using a combi-
nation of deductive (based on literature) and inductive (based on expert’s opinion) 
approaches were performed using NVIVOv10 Software. Results: A hierarchical 
structure of 100 nodes was designed around 2 main themes: LAIT and chronic graft-
rejection. According to expert interviews, LAIT is a common issue that can have 
significant health consequences. The main drivers of adherence were the number 
of pills and incidence of adverse events. The main consequences identified by the 
experts were antibody mediated graft-rejection and decreased graft survival. CHR 
was identified as the second most common cause of graft rejection between 2-3 
years post-transplant, behind death with a functioning graft. LAIT could cause up 
to 50% of CHR. There is no consensus on treating CHR, but therapies include intrave-
nous immunoglobulins, rituximab and plasmapheresis. Other health resources used 
include: at least one diagnostic renal biopsy, 2-fold increase in follow-up clinical 
visits, a higher risk of hospitalization due to complications (infections, heart-failure 
and anaemia) and preparation for return to dialysis. Most CHR episodes resulted in 
graft loss and return to dialysis with high associated costs. cOnclusiOns: Poor 
adherence is considered a preventable but frequent cause of CHR and graft loss. 
Treatment simplification and education could improve adherence and burden of 
disease for KT patients.
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Objectives: Published cost-effectiveness analysis (CEA) models, especially those 
which have been submitted to health technology assessment (HTA) authorities, 
are valuable in early phase CEA of interventions in the same or similar disease 
areas. However, even well-documented Markov models can be difficult to repli-
cate. Additionally, differences in disease states, treatment effects, and patient 
populations can render a successfully-replicated Markov model non-informative 
for early phase investigations. As a basis for future adaptation and expansion, 
a published chronic migraine CEA Markov model was replicated in TreeAge Pro 
2014 as both a Markov model and as an individual-based state-transition (Monte 
Carlo microsimulation [MCm]) model. MethOds: The published and replicated 
Markov model results were compared for both base case and sensitivity analyses. 
Patient subgroup Markov transition probability (MTP) matrices were implemented 
in the MCm, with assumptions regarding unpublished information on post-initial 
cycle state transitions. These assumptions involved subgroup treatment effects, 
patient decision discontinuation, and treatment stopping rules. The overall patient 
population (OPP) MTP matrices generated by the MCm were loaded into the Markov 
model to assess the validity of the assumptions. Results: Incremental costs 
and quality-adjusted life-years (QALYs) between intervention with onabotu-
linumtoxinA and placebo were produced. Differences between published and 
replicated Markov model incremental cost and QALY results were small for the 
base case (0.0%, -1.1%) and selected sensitivity analyses (maximum differences 
[1.9%, -1.9%]). Base case differences between published and the replicated Markov 
model (using MCm-derived OPP MTP matrices) incremental cost and QALY results 
were larger but acceptable (5.2%, 11.7%). This reflects the assumptions involved 
with the approximation of the patient subgroup MTP matrices. cOnclusiOns: 
The study demonstrates how a published model can be replicated and adapted 
for early phase CEA investigations, allowing for modeling of OPPs, treat-
ment effects, treatment discontinuation, etc. that differ from the published 
model.
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Objectives: To conduct pharmacoeconomic analyses, both cost and effective-
ness data are required. Randomized controlled trials (RCTs) are often used as a 
source of efficacy data. As RCTs are often of short duration, efficacy data need to 
be extrapolated beyond the trial follow-up period to be fit for use in model-based 
pharmacoeconomic evaluations. However, RCTs usually report effectiveness data in 
terms of Kaplan-Meier (KM) estimates. As a result, researchers need to reconstruct 
individual patient data (IPD) from published KM curves of trials’ treatment arms 
to estimate their long-term effects. This study aims to reconstruct the survival 
benefits of regorafenib monotherapy for previously treated metastatic colorectal 
cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, 
phase 3 trial. MethOds: An algorithm developed by Guyot and colleagues was 
adopted to reconstruct IPD using R statistical package, based on the overall survival 
KM curves of the CORRECT trial. The reconstruction of IPD included the following 
steps: 1) extraction of coordinates from published KM curves, 2) data accuracy check, 
3) creation of a second dataset, and application of the algorithm. The results of the 
original trial were compared to the reconstructed data using graphical and quantita-
tive methods, for validation purposes. Results: Based on the IPD reconstruction, 
162 and 88 events occurred in the regorafenib and placebo groups respectively. The 
median overall survival time in the regorafenib arm was 6.5 months (95% CI 5.83, 
8.43) which is about the same as the original trial (6.4 months). In the placebo group, 
the median overall survival for the reconstruction data was 5.09 months (95% CI 
4.30, 6.81) compared to the trial median survival of 5.0 months. cOnclusiOns: 
The results of this study can be utilized to estimate transition probabilities for 
model-based pharmacoeconomic evaluations in the absence of individual patient 
data (IPD).
